<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2022-27-50-56</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-2867</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДЕТСКАЯ ДЕРМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PEDIATRIC DERMATOLOGY</subject></subj-group></article-categories><title-group><article-title>Состояние полового развития у детей с врожденным буллезным эпидермолизом</article-title><trans-title-group xml:lang="en"><trans-title>State of sexual development in children with congenital epidermolysis bullosa</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5739-0941</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Леонова</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Leonova</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Леонова Мария Алексеевна, м.н.с. лаборатории патологии кожи у детей отдела научных исследований в педиатрии; ассистент кафедры дерматовенерологии</p><p>Москва</p></bio><bio xml:lang="en"><p>Leonova Maria A., junior researcher at Laboratory of Skin Pathology in Children of Department of Scientific Research in Pediatrics; assistant at Dept ofDermatovenereology </p><p> Moscow </p></bio><email xlink:type="simple">dr.maria.leonova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2252-8570</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мурашкин</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Murashkin</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мурашкин Николай Николаевич, д.м.н., проф., врач-дерматовенеролог, рук. НИИ детской дерматологии, зав. отделением дерматологии с группой лазерной хирургии, зав. лабораторией патологии кожи у детей; проф. кафедры педиатрии и детской ревматологии; проф. кафедры дерматовенерологии и косметологии; президент </p><p>Москва</p></bio><bio xml:lang="en"><p>Murashkin Nikolai N., DM Sci (habil.), professor, dermatovenereologist, head of Research Institute for Pediatric Dermatology, head of Dept of Dermatology with a group of laser surgery, head of Laboratory of Skin Pathology; professor at Dept of Pediatrics and Rheumatology; professor at Dept of Dermatovenereology and Cosmetology; president </p><p> Moscow </p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАУ «Национальный медицинский исследовательский центр здоровья детей» Минздрава России"&#13;
ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Centre for Children’s Health;&#13;
Russian National Research Medical University n.a. N.I. Pirogov</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАУ «Национальный медицинский исследовательский центр здоровья детей» Минздрава России;&#13;
ФГАОУ ВО «Первый Московский государственный медицинский университет И.М. Сеченова» Минздрава России (Сеченовский университет);&#13;
ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской Федерации; &#13;
МОО «Общество детских дерматологов»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Centre for Children’s Health;&#13;
First Moscow State Medical University n.a. I.M. Sechenov;&#13;
Central State Medical Academy of the Administration of the President of Russian Federation;&#13;
Interregional Public Organization ‘Society for Pediatric Dermatologists’</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>29</day><month>11</month><year>2022</year></pub-date><volume>1</volume><issue>27</issue><issue-title>Дерматология (2)</issue-title><fpage>50</fpage><lpage>56</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Леонова М.А., Мурашкин Н.Н., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Леонова М.А., Мурашкин Н.Н.</copyright-holder><copyright-holder xml:lang="en">Leonova M.A., Murashkin N.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/2867">https://www.med-alphabet.com/jour/article/view/2867</self-uri><abstract><p>Цель исследования. Оценить состояние полового развития у детей с ВБЭ.Методы. В данное исследование было включено 50 детей в возрасте от 8,11 до 17,80 года с ВБЭ, проходивших лечение в ФГАУ «НМИЦ здоровья детей» Минздрава России с декабря 2020 по апрель 2022 года. У всех пациентов оценивались антропометрические показатели, стадия полового развития по шкале Таннера, костный возраст, уровень гонадотропных (ФСГ, ЛГ) и половых (эстрадиол, тестостерон) гормонов, дополнительных гормональных показателей (кортизол, ДГЭА-сульфат, 17ОНР, АКТГ, пролактин, ТТГ, Т3, Т4, инсулин), УЗИ ОМТ у девочек и УЗИ ОМ у мальчиков, результаты психолого-педагогического обследования (опросник по С. Бэм, методика «рисунок человека» К. Маховер, тест Д. Векслера). Данные представлены с использованием медианы (Ме), квартилей 25 и 75 % [Q25; Q75] и стандартной ошибки (SE). Ввиду малого числа наблюдений для оценки значимости различий полученных показателей использовались непараметрические статистические критерии.Результаты. По результатам исследования была установлена статистически значимая связь возникновения отклонений в половом развитии у детей с ВБЭ с клинической формой заболевания (p &lt; 0,001). Степень тяжести клинических проявлений ВБЭ по шкале EBDASI была достоверно выше у детей в группе с отклонениями в половом развитии (р = 0,000). Антропометрические показатели BAZ и HAZ в группе детей с отклонениями в половом развитии были статистически значимо снижены (p = 0,000, p = 0,000 соответственно), что означает достоверно более высокую частоту развития недостаточности питания у данной когорты пациентов. Базальные уровни ФСГ и ЛГ (р = 0,000, р = 0,001 соответственно), эстрадиола и тестостерона (p = 0,002, р = 0,000 соответственно) были достоверно ниже у детей с отклонениями в половом развитии. Выявлена статистически значимая связь в исследуемых группах со стадией полового развития по шкале Таннера (р = 0,032). Cреди всех пациентов с ВБЭ (n = 50), ЗПР была диагностирована у 7 (14%) пациентов, при этом все пациенты страдали РДБЭ и имели низкий базальный уровень ЛГ, сниженные значения эстрадиола и тестостерона, что позволило установить им диагноз гипоГГ.Заключение. У пациентов с ВБЭ с наиболее тяжелой степенью клинических проявлений, сопровождающейся декомпенсированной недостаточностью питания многофакторного генеза, имеются отклонения в половом развитии и по достижению возраста 13 лет девочками и 14 лет мальчиками, может развиваться транзисторный (симптоматический) гипоГГ.</p></abstract><trans-abstract xml:lang="en"><p>Purpose of the study. Assess the state of sexual development in children with CEB.Methods and materials. The study included 50 children aged 8.11 to 17.80 years with CEB who were treated at the National Medical Research Centre for Children’s Health (Moscow, Russia) from December 2020 to April 2022. Anthropometric parameters, the stage of sexual development on the Tanner scale, bone age, the level of pituitary (FSH, LH) and sex (estradiol, testosterone) hormones, additional hormonal parameters (cortisol, DHEA-sulfate, 17OHP, ACTH, prolactin, TSH, T3, T4, insulin), ultrasound of the pelvic organs for girls and ultrasound of the scrotum organs in boys, the results of a psychological and pedagogical examination (questionnaire according to S. Bem, ‘drawing of a person’ by K. Machover, D. Wechsler’s test) were assessed in all patients. The data are presented using median (Me), quartiles of 25 and 75% [Q25; Q75] and standard error (SE). Due to the small number of observations, nonparametric statistical criteria were used to assess the significance of the differences in the obtained indicators.Results. According to the results of the study, a statistically significant relationship was established between the occurrence of deviations in sexual development in children with CEB and the clinical form of the disease (p &lt; 0,001). The severity of clinical manifestations of CEB according to the EBDASI scale was significantly higher in children in the group with deviations in sexual development (p = 0,000) compared with the group of children with normal sexual development. Anthropometric indicators of BAZ and HAZ in the group of children with deviations in sexual development were statistically significantly reduced (p = 0.000, p = 0.000, respectively) compared with children with normal sexual development, which means a significantly higher incidence of malnutrition in this cohort of patients. Basal levels of FSH and LH (p = 0,000, p = 0,001, respectively), estradiol and testosterone (p = 0,002, p = 0,000, respectively) were significantly lower in children with abnormalities in sexual development compared with children with normal sexual development. A statistically significant relationship was revealed in the studied groups with the stage of sexual development according to Tanner scale (p = 0,032). Among all patients with CEB (n = 50), delay puberty was diagnosed in 7 patients (14%), while all patients suffered from RDEB and had low basal LH levels, reduced estradiol and testosterone values, which allowed them to be diagnosed with hypogonadotropic hypogonadism (HH).Conclusions. In patients with CEB with the most severe degree of clinical manifestations, accompanied by decompensated malnutrition of multifactorial genesis, there are deviations in sexual development and upon reaching the age of 13 years, girls and boys develop transient (symptomatic).</p></trans-abstract><kwd-group xml:lang="ru"><kwd>врожденный буллезный эпидермолиз</kwd><kwd>половое развитие</kwd><kwd>задержка полового развития</kwd><kwd>недостаточность питания</kwd><kwd>EBDASI</kwd></kwd-group><kwd-group xml:lang="en"><kwd>congenital epidermolysis bullosa</kwd><kwd>sexual development</kwd><kwd>delayed sexual development</kwd><kwd>malnutrition</kwd><kwd>EBDASI</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Fine JD, Bruckner-Tuderman L, Eady RA, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014 Jun; 70 (6): 1103–26. DOI: 10.1016/j.jaad.2014.01.903. Epub 2014 Mar 29. PMID: 24690439.</mixed-citation><mixed-citation xml:lang="en">Fine JD, Bruckner-Tuderman L, Eady RA, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014 Jun; 70 (6): 1103–26. DOI: 10.1016/j.jaad.2014.01.903. Epub 2014 Mar 29. PMID: 24690439.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Has C, Fischer J. Inherited epidermolysis bullosa: New diagnostics and new clinical phenotypes. Exp Dermatol. 2019 Oct; 28 (10): 1146–1152. DOI: 10.1111/exd.13668. Epub 2018 Jun 28. PMID: 29679399.</mixed-citation><mixed-citation xml:lang="en">Has C, Fischer J. Inherited epidermolysis bullosa: New diagnostics and new clinical phenotypes. Exp Dermatol. 2019 Oct; 28 (10): 1146–1152. DOI: 10.1111/exd.13668. Epub 2018 Jun 28. PMID: 29679399.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Has C, Bauer JW, Bodemer C, Bolling MC, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020 Oct; 183 (4): 614–627. DOI: 10.1111/bjd.18921. Epub 2020 Mar 11. PMID: 32017015.</mixed-citation><mixed-citation xml:lang="en">Has C, Bauer JW, Bodemer C, Bolling MC, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020 Oct; 183 (4): 614–627. DOI: 10.1111/bjd.18921. Epub 2020 Mar 11. PMID: 32017015.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J Am Acad Dermatol. 2009 Sep; 61 (3): 367–84; quiz 385–6. DOI: 10.1016/j.jaad.2009.03.052. PMID: 19700010.</mixed-citation><mixed-citation xml:lang="en">Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J Am Acad Dermatol. 2009 Sep; 61 (3): 367–84; quiz 385–6. DOI: 10.1016/j.jaad.2009.03.052. PMID: 19700010.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol. 2009 Sep; 61 (3): 387–402; quiz 403–4. DOI: 10.1016/j.jaad.2009.03.053. PMID: 19700011.</mixed-citation><mixed-citation xml:lang="en">Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol. 2009 Sep; 61 (3): 387–402; quiz 403–4. DOI: 10.1016/j.jaad.2009.03.053. PMID: 19700011.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Макарова С.Г., Намазова-Баранова Л.С., Мурашкин Н.Н., Епишев Р.В., Чумбадзе Т.Р., Петровская М.И., Митюшин И.Л. Коррекция нутритивного статуса в комплексной терапии детей, страдающих дистрофической формой врожденного буллезного эпидермолиза. Педиатрическая фармакология. 2016; 13 (6): 577–86.</mixed-citation><mixed-citation xml:lang="en">Makarova S.G., Namazova-Baranova L.S., Murashkin N.N., Epishev R.V., Chumbadze T.R., Petrovskaya M.I., Mityushin I.L. Correction of nutritional status in the complex therapy of children suffering from a dystrophic form of congenital epidermolysis bullosa. Pediatric Pharmacology. 2016; 13 (6): 577–86.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Simon D. Puberty in chronically diseased patients. Horm Res. 2002; 57 Suppl 2: 53–6. DOI: 10.1159/000058102. PMID: 12065928.</mixed-citation><mixed-citation xml:lang="en">Simon D. Puberty in chronically diseased patients. Horm Res. 2002; 57 Suppl 2: 53–6. DOI: 10.1159/000058102. PMID: 12065928.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Palmert MR, Dunkel L. Clinical practice. Delayed puberty. N Engl J Med. 2012 Feb 2; 366 (5): 443–53. DOI: 10.1056/NEJMcp1109290. PMID: 22296078.</mixed-citation><mixed-citation xml:lang="en">Palmert MR, Dunkel L. Clinical practice. Delayed puberty. N Engl J Med. 2012 Feb 2; 366 (5): 443–53. DOI: 10.1056/NEJMcp1109290. PMID: 22296078.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Dye AM, Nelson GB, Diaz-Thomas A. Delayed Puberty. Pediatr Ann. 2018 Jan 1; 47 (1): e16–e22. DOI: 10.3928/19382359–20171215–01. PMID: 29323692.</mixed-citation><mixed-citation xml:lang="en">Dye AM, Nelson GB, Diaz-Thomas A. Delayed Puberty. Pediatr Ann. 2018 Jan 1; 47 (1): e16–e22. DOI: 10.3928/19382359–20171215–01. PMID: 29323692.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wolf RM, Long D. Pubertal Development. Pediatr Rev. 2016 Jul; 37 (7): 292–300. DOI: 10.1542/pir.2015–0065. PMID: 27368360.</mixed-citation><mixed-citation xml:lang="en">Wolf RM, Long D. Pubertal Development. Pediatr Rev. 2016 Jul; 37 (7): 292–300. DOI: 10.1542/pir.2015–0065. PMID: 27368360.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Tang C, Zafar Gondal A, Damian M. Delayed Puberty. 2021 Aug 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. PMID: 31335042.</mixed-citation><mixed-citation xml:lang="en">Tang C, Zafar Gondal A, Damian M. Delayed Puberty. 2021 Aug 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. PMID: 31335042.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Young J, Xu C, Papadakis GE, Acierno JS, et al. Clinical Management of Congenital Hypogonadotropic Hypogonadism. Endocr Rev. 2019 Apr 1; 40 (2): 669–710. DOI: 10.1210/er.2018–00116. PMID: 30698671.</mixed-citation><mixed-citation xml:lang="en">Young J, Xu C, Papadakis GE, Acierno JS, et al. Clinical Management of Congenital Hypogonadotropic Hypogonadism. Endocr Rev. 2019 Apr 1; 40 (2): 669–710. DOI: 10.1210/er.2018–00116. PMID: 30698671.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Wei C, Davis N, Honour J, et al. The investigation of children and adolescents with abnormalities of pubertal timing. Ann Clin Biochem. 2017 Jan; 54 (1): 20–32. DOI: 10.1177/0004563216668378. Epub 2016 Sep 28. PMID: 27555666.</mixed-citation><mixed-citation xml:lang="en">Wei C, Davis N, Honour J, et al. The investigation of children and adolescents with abnormalities of pubertal timing. Ann Clin Biochem. 2017 Jan; 54 (1): 20–32. DOI: 10.1177/0004563216668378. Epub 2016 Sep 28. PMID: 27555666.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Martinez AE, Allgrove J, Brain C. Growth and pubertal delay in patients with epidermolysis bullosa. Dermatol Clin. 2010 Apr; 28 (2): 357–9, XII. DOI: 10.1016/j.det.2010.01.007. PMID: 20447503.</mixed-citation><mixed-citation xml:lang="en">Martinez AE, Allgrove J, Brain C. Growth and pubertal delay in patients with epidermolysis bullosa. Dermatol Clin. 2010 Apr; 28 (2): 357–9, XII. DOI: 10.1016/j.det.2010.01.007. PMID: 20447503.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Loh CC, Kim J, Su JC, Daniel BS, et al. Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). J Am Acad Dermatol. 2014 Jan; 70 (1): 89–97. e1–13. DOI: 10.1016/j.jaad.2013.09.041. PMID: 24355263.</mixed-citation><mixed-citation xml:lang="en">Loh CC, Kim J, Su JC, Daniel BS, et al. Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). J Am Acad Dermatol. 2014 Jan; 70 (1): 89–97. e1–13. DOI: 10.1016/j.jaad.2013.09.041. PMID: 24355263.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Эндокринология. Национальное руководство. Краткое издание. Под ред. И.И. Дедова, Г.А. Мельниченко. М.: ГЭОТАР-Медиа, 2013. 752 с. ISBN978–5–9704–2471–1.</mixed-citation><mixed-citation xml:lang="en">Endocrinology. National guidelines. Short edition. Ed. I.I. Dedov, G.A. Melnichenko. M.: GEOTAR-Media, 2013. 752 p. ISBN978–5–9704–2471–1.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
